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Methicillin-resistant Staphylococcus aureus is a frequent cause of hospital-associated infections, including 
central catheter–associated bacteremia. Vancomycin has been the drug of choice for treating this type 
of bacteremia for decades in patients who have no contraindications to the antibiotic. However, resistance 
to vancomycin is an emerging problem. Newer antibiotics approved by the Food and Drug Administration 
have activity against methicillin-resistant S aureus. Some of the antibiotics also have activity against strains 
of S aureus that are intermediately susceptible or resistant to vancomycin. This article uses a case study 
to highlight the clinical signs of vancomycin failure and describes the indications for and appropriate use 
of alternative antimicrobials such as ceftaroline, daptomycin, linezolid, tigecycline, and telavancin. (Critical 
Care Nurse. 2016;36[4]:46-57)
©2016 American Association of Critical-Care Nurses doi: http://dx.doi.org/10.4037/ccn2016475
According to the Centers for Disease Control and Prevention, methicillin-resistant Staphylo-coccus aureus (MRSA) is a leading cause of heath care–associated infections. It is responsible for more than 75 000 severe infections and approximately 11 000 deaths each year in the United 
States.1 S aureus is both a commensal skin organism and a pathogen. Colonization can lead to infection 
when a breach occurs in the skin or mucosal defense systems because of trauma or common procedures 
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such as surgery or placement of a central catheter.2 Sev-
eral different risk factors have been reported for MRSA 
infections (Table 1) in inpatients, including patients with 
central intravenous catheters.3-6 MRSA is a common cause 
of bacteremia and is the causative organism reported in 
7.4% of central catheter–associated bloodstream infections 
(CLABSIs) in critical care patients.1,7 CLABSIs occur in 
approximately 80 000 critically ill patients annually in 
the United States. The infections are associated with 
prolonged stays in the intensive care unit (ICU) and the 
hospital and with increases in overall health care costs.8,9 
Prevention of CLABSI is necessary to achieve goals for 
patient safety and maximize hospital reimbursement 
from the Centers for Medicare and Medicaid Services.10 
Accordingly, the Centers for Disease Control and Pre-
vention collaborated with other organizations to develop 
guidelines11 and checklists12 to help clinicians and health 
care facilities prevent CLABSIs. This emphasis on preven-
tive measures has contributed to an almost 50% decrease 
in CLABSIs due to MRSA from 1997 to 2007.7 
For patients with suspected CLABSI, the guidelines 
of the Infectious Diseases Society of America (IDSA)9 
recommend starting systemic antimicrobial therapy 
after blood for culturing has been obtained and, if pos-
sible, removing the intravascular catheter. Initial empiric 
therapy should include drugs effective against gram- 
positive organisms commonly found on the skin, 
including S aureus. Most patients with suspected CLABSI 
are given vancomycin because of the increased preva-
lence of MRSA in health care settings, and combination 
therapy with a drug effective against a broad spectrum 
of gram-negative organisms should be considered for 
patients who are critically ill or immunocompromised.9 
Definitive treatment of a CLABSI depends on the caus-
ative organism, removal of the infected catheter, patient- 
specific factors, and complications. Vancomycin remains 
the first-line option for treatment of documented MRSA 
bacteremia.6,9 However, several antimicrobial agents are 
effective against nosocomial MRSA infections. Each agent 
differs in the mechanism of action, indications for use, 
clinical and laboratory monitoring required, and adverse 
effects. Unfortunately, data are limited on use of these 
agents in patients with MRSA bacteremia, including CLABSI.
In this article, we present the case study of a patient 
with CLABSI due to MRSA who required alternative 
antibiotic therapy to eradicate the infection, and we 
discuss other agents that may be used to treat MRSA 
CLABSIs. Identifying information has been changed to 
protect the patient’s privacy and confidentiality.
Vancomycin
Vancomycin has been used to treat penicillin-resistant 
infections for more than 50 years and is the first-line 
treatment option for MRSA CLABSI6,9 (Table 2). Vanco-
mycin is widely available and costs less than newer 
antibiotics designed to treat MRSA infections.19 However, 
determining the best dosage is difficult, tissue penetra-
tion is highly variable, routine trough-level monitoring 
is required, and infusion-related reactions and anaphy-
laxis can occur. Vancomycin also can be nephrotoxic.13 
In addition to these disadvantages, unsuccessful 
Table 1  Risk factors for hospital-acquired infection 
with methicillin-resistant Staphylococcus aureus (MRSA)
Antibiotic treatment in the past 90 days
Hospital stay of 5 or more days within the past 12 months
Residence in a long-term care facility
Open skin wound and/or central intravenous catheter, 
including hemodialysis patients
Recent major surgery
Medical condition causing immunosuppression
Hospital stay at a health care facility with high rates of 
MRSA infection
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treatment and increased mortality have been documented 
in patients who require elevated concentrations of van-
comycin to inhibit growth of MRSA isolates. Isolates 
that require elevated levels of the antibiotic encompass 
those reported as intermediately susceptible or resistant 
to vancomycin (minimum inhibitory concentrations 
[MICs] <2 μg/mL) and those for which the vancomycin 
MIC is 2 μg/mL; the latter isolates are still reported as 
sensitive under current laboratory standards.6,13,20 As a 
result, the IDSA vancomycin guidelines13 suggest that an 
alternative agent should be considered in MRSA infec-
tions for which the vancomycin MIC is 2 μg/mL or less, 
particularly if the patient is not responding to treatment. 
Alternative agents are also recommended in patients who 
have persistent bacteremia during therapy with vancomy-
cin regardless of the reported MIC value (vancomycin 
failures).6 Although vancomycin remains the drug of 
choice, alternative agents may be used to treat invasive 
MRSA infections (Table 2).6,9,13-19 Alternative MRSA ther-
apy is based on the reported MIC values, bactericidal 
activity, antibiotic penetration at the infection site, and 
patient comorbid conditions, including reduced renal func-
tion.6,21 See Table 3 for antibiotic pharmacology definitions.
Alternative Treatments for MRSA Infections
Daptomycin
Daptomycin (Cubicin) is a lipopeptide antibacterial 
agent that has rapid bactericidal activity against aerobic 
CASE STUDY
A 71-year-old woman was transferred to a tertiary care center from an outside facility because of acute exacerbation of chronic heart failure and 
moderate dyspnea. Her medical history included isch-
emic cardiomyopathy with an ejection fraction of 20%, 
coronary artery bypass grafting and placement of an 
automated internal cardioverter defibrillator because 
of coronary artery disease, type 2 diabetes mellitus, 
stage III chronic kidney disease with baseline level of 
serum creatinine 1.2 mg/dL (to convert to micromoles 
per liter, multiply by 88.4) and glomerular filtration rate 
47.9 mL/min per 1.73 m2. Within a few hours of admis-
sion, her condition deteriorated; oxygen saturation was 
88% on 100% oxygen via a nonrebreather mask, and she 
was transferred to the cardiac ICU, where noninvasive 
positive pressure ventilation was started. A central cath-
eter was placed, and a dobutamine infusion was started 
for inotropic support. An indwelling bladder catheter 
was placed for accurate monitoring of fluid intake and 
output. Furosemide 40 mg was administered intrave-
nously every 8 hours for 3 doses to induce diuresis. 
The patient responded well to the medications. As her 
condition improved, she was weaned to 2 L of oxygen 
via nasal cannula and transferred to the cardiac step-
down unit, where the dobutamine infusion was slowly 
discontinued during the next 48 hours. The bladder 
catheter was subsequently removed.
On hospital day 5, she became lethargic and febrile. 
Vital signs were temperature 103°F (39.4°C), blood 
pressure 105/48 mm Hg, heart rate 102/min (sinus 
tachycardia), respirations 22/min, and oxygen 
saturation 94% on 2 L of oxygen via nasal cannula. Lab-
oratory studies revealed a serum level of creatinine of 
2.0 mg/dL and a white blood cell count of 14 500/μL. 
Severe sepsis and acute-on-chronic kidney failure were 
suspected. Samples were obtained for pan cultures (ie, 
pair of blood cultures, urinalysis with culture and sensi-
tivity, sputum sample if a productive cough is present). 
A chest radiograph revealed mild pulmonary vascular con-
gestion without infiltrates. Central venous pressure was 
12 mm Hg. The serum level of lactic acid was 2.4 mg/dL 
(to convert to millimoles per liter, multiply by 0.111). 
The patient was empirically started on broad-spectrum 
antibiotics, including intravenous vancomycin and 
cefepime. Urinalysis showed no pyuria, and urine culture 
was negative for microorganisms. Both blood cultures 
initially showed gram-positive cocci in clusters. Final 
culture results were positive for MRSA bacteremia, 
with a minimum inhibitory concentration of 1 μg/mL 
for vancomycin. Cefepime was discontinued. Peripheral 
intravenous access was obtained, and the central cathe-
ter was removed. Despite treatment with vancomycin, 
the patient’s clinical status did not improve. She remained 
febrile and had worsening leukocytosis. Vancomycin 
was discontinued, and daptomycin was started for 
complicated MRSA bacteremia. The patient’s condition 
rapidly improved with the change in antibiotic. Her fever 
and leukocytosis resolved. Repeat blood cultures were 
negative for microorganisms. Daptomycin was contin-
ued for 4 weeks after the first blood culture negative 
for MRSA was obtained. The patient was eventually 
discharged to acute inpatient rehabilitation.
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Table 2  Treatment options for bacteremia and central catheter–associated bloodstream infections
due to methicillin-resistant Staphylococcus aureus (MRSA)
Feature 
Common dosing
Route
Infusion times
Renal dose 
adjustment
Effect on MRSA
Mechanism of 
action
Recommendations 
per IDSA MRSA 
2011 guidelines6
Recommendations 
per IDSA CRBSI 
2009 guidelines9
Laboratory 
monitoring
Drug cost (AWP) 
per day for a 
75-kg patient,19
$
Ceftaroline18 
600 mg every 
12 h
Intravenous
60 min
Yes
Bactericidal, 
time 
dependent
Inhibits bacterial 
cell wall 
synthesis
Not applicable
Not applicable
SCr routinely
303.24
Tigecycline17 
100 mg x1 then 
50 mg every 12 h
Intravenous
30-60 min
No
Bacteriostatic
Inhibits bacterial 
protein synthesis 
by blocking the 
binding of trans-
fer RNA to the 
bacterial 
ribosome 
Not recommended 
in IDSA MRSA 
2011 guidelines 
because of a 
study that showed 
increased risk of 
death compared 
with risk with 
other agents 
Not applicable
Monitor for 
increases in 
INR if patient is 
receiving 
warfarin 
concomitantly
243.20 
Telavancin16 
10 mg/kg 
every 24 h
Intravenous
60 min
Yes
Bactericidal, 
concentration 
dependent
2 mechanisms: 
inhibits cell 
wall synthesis 
and disrupts 
cell membrane 
function
Persistent 
bacteremia
Not applicable
SCr at least 
every 2-3 days
Pregnancy 
test before 
start of 
treatment
Can interfere 
with coagula-
tion tests and 
falsely increase 
clotting times 
371.36
Daptomycin15 
6-10 mg/kg
every 24 h
Intravenous
2-min intravenous
bolus or 30-min
infusion
Yes
Bactericidal, 
concentration 
dependent
Binds the cell 
membrane and 
causes rapid 
depolarization
Bacteremia
Persistent 
bacteremia 
Alternative MRSA 
treatment option 
CPK weekly
SCr routinely
Can interfere 
with coagula-
tion tests and 
falsely increase 
clotting times
425.66
Linezolid14 
600 mg every 
12 h
Intravenous 
and oral
30-120 min
No
Bacteriostatic
Inhibits 
 bacterial 
protein 
synthesis 
Persistent 
bacteremia
Alternative 
MRSA treat-
ment option
Should not be 
used 
empirically
CBC weekly 
(platelet 
monitoring)
501.90 
intravenous 
Vancomycin13 
15-20 mg/kg
every 8-12 h
Intravenous
Minimum of 
60 min
Yes
Slowly bactericidal
Inhibits bacterial 
cell wall synthesis
  Bacteremia 
Preferred empiric 
and MRSA  
treatment option
SCr routinely
At least 1 steady-
state trough 
concentration, 
repeated as clini-
cally appropriate
Periodic WBC, if 
prolonged 
therapy
15.00 
Abbreviations: AWP, average wholesale price; CBC, complete blood cell count; CPK, creatine phosphokinase; CRBSI, catheter-related bloodstream infection;  
IDSA, Infectious Diseases Society of America; INR, international normalized ratio; SCr, serum creatinine; WBC, white blood cell count.
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gram-positive bacteria, including MRSA15 (Table 2). 
Daptomycin has been approved by the Food and Drug 
Administration (FDA) for treatment of MRSA bactere-
mia, including right-sided endocarditis. In the IDSA 
guidelines, the antibiotic is recommended as a first-line 
option for MRSA bacteremia. Daptomycin is a concentration- 
dependent antibiotic, and higher doses of 8 to 10 mg/
kg per day may be considered for more invasive infec-
tions.6,15 Clinical success rates are similar for daptomycin 
and vancomycin (44.4% vs 31.8%; P = .28) in patients 
with MRSA bacteremia and endocarditis.22 In addition, 
daptomycin may be preferred over vancomycin in 
MRSA bacteremia caused by isolates with vancomycin 
MIC values greater than 1 μg/mL because of improved 
patient outcomes. Murray et al23 conducted a matched 
retrospective cohort study (n = 170) in patients with 
MRSA bacteremia with elevated vancomycin MIC 
values (for 94.1% of the bacterial isolates, the MIC of 
vancomycin was 2 μg/mL). Compared with the control 
group, patients in the daptomycin group had signifi-
cantly lower rates of unsuccessful treatment (20.0% vs 
48.2%; P < .001), lower 30-day mortality (3.5% vs 12.9%; 
P = .05), and lower rates of persistent bacteremia (18.8% 
vs 42.4%; P = .001). In patients with persistent bactere-
mia and unsuccessful treatment with vancomycin, high-
dose daptomycin (10 mg/kg per day) in combination 
with another agent to which the MRSA isolate is sus-
ceptible is a recommended option per IDSA guidelines.6 
However, combination therapy is not routinely used in 
clinical practice because of the lack of supporting 
clinical evidence.
Although daptomycin has solid clinical data to sup-
port its use in MRSA bacteremia, treatment with this 
antibiotic has drawbacks. Daptomycin should not be 
used in patients with suspected pneumonia because 
the drug is inactivated by pulmonary surfactant. Serious 
adverse events reported include myopathy and rhabdo-
myolysis. Serum levels of creatinine phosphokinase 
should be checked weekly during the treatment to 
monitor for development of toxic musculoskeletal effects. 
Concomitant use of other agents that may cause myopa-
thy, including inhibitors of 3-hydroxy-3-methyl-glutaryl- 
coenzyme A reductase (statins), may increase the risk 
of increasing the levels of creatinine phosphokinase and 
should be avoided if possible.15 Data are limited on the 
coadministration of daptomycin and statins, and results 
of a recent retrospective observational study24 indicated 
a slightly higher incidence of elevations in creatinine 
phosphokinase level when combination therapy was used 
(6.1% vs 2.9%; P = .38). Elevations in phosphokinase level 
rarely result in discontinuation of therapy. However, 
discontinuation of therapy should be considered in 
patients with myopathy and concurrent elevations in the 
enzyme level (5 times the upper limit of the reference 
range) or in patients with elevations 10 times or greater 
than the upper limit of the reference range. Clinicians may 
also consider stopping administration of statins temporar-
ily while the patient is being treated with daptomycin.15 
Table 3  Antibiotic pharmacology definitionsa 
Term 
Bactericidal
Bacteriostatic
Minimum inhibitory concentration (MIC)
Concentration-dependent killing
Time-dependent killing
Volume of distribution (Vd)
Definition  
Agents that kill bacteria.
Agents that halt bacterial growth.
Smallest concentration of antibiotic required to inhibit the growth of bacteria. 
Antibiotic activity that depends on the peak blood concentrations of the antibiotic in 
relation to the MIC for the specific organism, with higher peak concentrations result-
ing in optimized bacterial killing.
Antibiotic activity that depends on the maintenance of antibiotic blood concentrations 
greater than the MIC of the specific organism for the specified part of the dosing 
interval. The optimal amount of time the concentration remains about the MIC varies 
depending on the antibiotic. 
The theoretical volume or space within the body that a drug occupies, resulting in the 
measured drug concentration in the patient’s serum. Larger volumes of distribution 
generally indicate that a drug distributes well into various tissues in the body, whereas 
smaller volumes of distribution indicate that a drug is predominately contained within 
the intravascular space.
a Based on information from Pankey and Sabath.21
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Other rare adverse effects include eosinophilic pneumo-
nia, peripheral neuropathy, and anaphylaxis. In addition, 
daptomycin may falsely prolong prothrombin time and 
elevate the international normalized ratio.15
Linezolid
Linezolid (Zyvox) was approved by the FDA in 2000. 
This member of the oxazolidinone class has bacteriostatic 
activity against aerobic gram-positive bacteria and against 
multidrug-resistant gram-positive organisms, including 
MRSA and organisms with reduced susceptibility to van-
comycin (Table 2).14 Although linezolid is recommended 
for treatment of several different MRSA infections, it is 
not a first-line empiric or definitive treatment option in 
MRSA bacteremia, including CLABSIs.6 Available data do 
support use of linezolid as an alternative agent in MRSA 
bacteremia. The effectiveness of linezolid as definitive 
treatment for MRSA bacteremia was shown in an obser-
vational compassionate use program25 as well as a 
pooled analysis26 of data from 5 randomized controlled 
trials that showed similar clinical cure rates for vanco-
mycin and linezolid (46% vs 56%; odds ratio, 1.47; 95% 
CI, 0.50-4.31). Additionally, findings of an open- label 
randomized controlled study27 published in 2009 indi-
cated that linezolid and vancomycin treatment of MRSA 
CLABSIs had similar successful clinical outcomes (79% 
vs 76%; 95% CI, -21 to 27). However, further analysis of 
data on patients with suspected CLABSIs whose cultures 
were negative for microorganisms or positive for gram- 
negative pathogens, the linezolid group had a higher 
mortality rate than did the comparative group (21.5% 
vs 16%). Because of these data, the FDA issued an 
update for the linezolid package insert to state that 
linezolid should not be used for treatment of CLABSI.14 
In the IDSA guidelines,6,9 linezolid is recommended solely 
as an alternative agent for patients with documented or 
persistent MRSA bacteremia. 
Prolonged linezolid therapy may increase the risk for 
hematological toxic effects (thrombocytopenia, anemia, 
and neutropenia), peripheral neuropathy, and lactic aci-
dosis.14 Complete blood cell counts should be monitored 
in patients receiving linezolid for longer than 2 weeks to 
assess for myelosuppression. Linezolid is a monoamine 
oxidase inhibitor that places patients at risk for serotonin 
syndrome when they are receiving other serotonergic 
agents. Concurrent use of linezolid and serotonergic 
agents should be avoided if possible, and the FDA has 
specific recommendations for handling this drug interac-
tion when simultaneous administration is necessary.14,28
Telavancin
Telavancin (Vibativ) is a bactericidal lipoglycopeptide 
antibiotic approved by the FDA in 2009. It has 2 mecha-
nisms of action against gram-positive organisms, a char-
acteristic that makes it unique16 (Table 2). The IDSA 
guidelines for treatment of MRSA infections reserve it 
for salvage therapy in patients with MRSA bacteremia 
caused by isolates with reduced susceptibility to vanco-
mycin or patients whose treatment with vancomycin was 
unsuccessful.6 In a phase 2 randomized study,29 telavancin 
was com-
pared with 
standard 
therapy for 
the treatment 
of uncom-
plicated S aureus bacteremia. Of the 30 patients with 
uncomplicated MRSA bacteremia, 29 experienced a clinical 
cure. In this study with a small number of patients, patients 
treated with telavancin had a higher incidence of adverse 
events (90%) than did patients who received standard 
therapy (72%); nephrotoxic effects were the most common. 
Telavancin should be used solely as an alternative 
agent when the anticipated benefits outweigh the risks 
of exposure to the antibiotic. Adverse events include 
nephrotoxic effects, taste disturbances, and a prolonged 
QT interval.16 Telavancin is contraindicated in patients 
with prolonged QT intervals, severe left ventricular 
hypertrophy, and decompensated heart failure. The 
manufacturer recommends pregnancy testing before 
treatment with this antibiotic for women who are non-
menopausal and have not had a tubal ligation, hysterec-
tomy, or bilateral oophorectomy because of the risk of 
fetal harm. Infusions of telavancin should be adminis-
tered during a period of at least 60 minutes to avoid the 
risk of reactions, including flushing of the upper part of 
the body, rash, and pruritus, all of which also can occur 
with rapid administration of vancomycin. Telavancin does 
not affect blood coagulation; however, anticoagulation 
test results are falsely altered, similar to the alterations 
caused by daptomycin. In order to ensure more accurate 
results, blood samples for coagulation studies should be 
obtained just before the next scheduled dose of telavancin 
to allow the effects on the test results to decrease.16 
Linezolid is recommended only  
as an alternative agent for patients 
with documented or persistent MRSA 
bacteremia.
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Tigecycline
Tigecycline (Tygacil), a glycylcycline antibiotic 
approved by the FDA in 2005, has bacteriostatic activity 
against MRSA17 (Table 2). The current IDSA MRSA 
guidelines do not include tigecycline because of its black 
box warning for increased mortality and the availability 
of other agents active against MRSA.6 This black box 
warning was based on an increased 30-day mortality 
reported in a meta-analysis with data from phase 3 and 
4 trials.30,31 The highest mortality risk occurred in patients 
treated with tigecycline for ventilator-associated pneu-
monia. In addition to the increased mortality, blood 
levels of tigecycline are low because of its large volume 
of distribution32 (Table 2). This pharmacokinetic prop-
erty of the drug along with its bacteriostatic activity has 
called into question its effectiveness in patients with 
bacteremia. No studies on its use for primary MRSA 
bacteremia have been published. 
The effectiveness of tigecycline in patients with sec-
ondary bacteremia was evaluated in an analysis of pooled 
data from 8 multicenter trials.33 Gardiner et al33 reported 
that tigecycline was effective for patients with bacteremia 
associated with community-acquired bacterial pneumonia, 
complicated skin/skin-structure infections, and intra- 
abdominal 
infections; 
however, 
only 6 
patients in 
the tigecy-
cline group had MRSA bacteremia. Adverse effects 
include severe nausea and vomiting, severe skin reactions, 
QT prolongation, pancreatitis, and hepatotoxic effects. 
Drug interactions with tigecycline are uncommon; how-
ever, the antibiotic may alter the clearance of warfarin, 
resulting in an increased international normalized ratio. 
The international normalized ratio should be monitored 
when tigecycline and warfarin are administered concom-
itantly.17 On the basis of the current literature, tigecycline 
cannot be recommended for treatment of primary 
MRSA bacteremia, including MRSA CLABSI.
Ceftaroline 
Ceftaroline (Teflaro) is a bactericidal cephalosporin18 
(Table 2). Ceftaroline’s specific affinity for penicillin- 
binding proteins 2a and 2x makes it effective against 
Streptococcus pneumoniae and S aureus, including MRSA.34 
Ceftaroline is not included in the 2011 IDSA MRSA 
guidelines because the antibiotic had not been approved 
by the FDA when the guidelines were published.6 Since 
publication of the guidelines, several retrospective studies 
and case reports on use of this antibiotic, both as mono-
therapy and in combination with other agents, for treat-
ment of MRSA bacteremia have been published.35-40 
Polenakovik and Pleiman39 reported clinical success with 
ceftaroline therapy in 23 of 31 patients (74.2%) with 
MRSA bacteremia. The sample included 7 patients with 
intravenous catheter–associated MRSA infections and 
10 patients given combination MRSA therapy. The most 
common reason for use of ceftaroline was elevated MIC 
values (MIC >1 μg/mL) for vancomycin. 
More recently, in a multicenter retrospective case- 
control study (n = 32),38 ceftaroline salvage therapy 
(started after 5 days of vancomycin therapy) was com-
pared with vancomycin alone in treating MRSA bacteremia 
caused by organisms for which MIC levels for vancomy-
cin were higher (≥2 μg/mL). Time to eradication of 
MRSA was significantly shorter (P = .06) with ceftaroline 
(4 days) than with vancomycin (8 days), and clinical 
success at the end of treatment was significantly higher 
(P = .06) for ceftaroline (81%) than for vancomycin (44%). 
In another retrospective study, Casapao et al35 ana-
lyzed ceftaroline use at several sites during a 2.5-year 
period. Of the 527 patients included in the study, 241 
(45.7%) had documented MRSA infections. Bacteremia 
was reported in 48 patients (28.1%); in 10 of the 48, the 
infections were associated with use of intravenous cathe-
ters. The majority of patients (80.1%) were treated with 
vancomycin before therapy with ceftaroline was started; 
the median duration of vancomycin therapy was 3 days. 
Clinical success was achieved in 79% of the bacteremia 
subgroup (112 of 141 patients). The success rate was 79% 
with both the standard dosing and the off-label dosing 
(600 mg intravenously every 8 hours). 
Combination therapy with ceftaroline has also been 
reported. Sakoulas et al40 used ceftaroline plus daptomy-
cin for 26 patients with documented refractory staphylo-
coccal bacteremia. Patients had persistent bacteremia for 
median of 10 days with previous therapy. Among the 26 
patients, 20 had MRSA infections and 14 had endocarditis. 
After combination therapy was started, the median time 
to bacteremia clearance was 2 days (range, 1-6 days). 
This increasing amount of evidence helps support 
the notion that ceftaroline may be considered as an 
Ceftaroline may be considered as an 
alternative antibiotic in instances when 
patients have disease progression on 
standard therapy.
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alternative antibiotic in the treatment of MSRA bactere-
mia and CLABSIs, including instances when patients 
have disease progression on standard therapy.
Adverse events reported with ceftaroline are minimal 
and are similar to those associated with other cephalo-
sporins. Hypersensitivity reactions to penicillins and 
carbapenems should be considered before therapy with 
ceftaroline is started because most likely cross-reactivity 
exists between ?-lactam antibiotics.18 In addition to 
common adverse events associated with treatment with 
?-lactam antibiotics, case reports have described the 
development of eosinophilic pneumonia.41
Nursing Care 
Although appropriate antibiotic therapy is a key element 
in managing CLABSI due to MRSA, instituting evidence- 
based infection control measures is required to prevent the 
spread of MRSA and other multidrug-resistant organisms. 
Multiple studies have shown that decreasing the skin’s 
bacterial load with chlorhexidine gluconate (CHG) baths 
decreases rates of infection with MRSA and other patho-
gens. CHG is a topical antiseptic active against a large 
number of both gram-positive and gram-negative microbes. 
Bathing patients with 2% CHG solution is recommended 
by the Centers for Disease Control and Prevention for 
preventing CLABSIs.11 
In addition to CHG bathing and other methods of 
decolonization, such as administering mupirocin ointment 
intranasally, consistently applying infection prevention 
and control practices can halt the spread of infections due 
to multidrug- resistant organisms. Research42 has indi-
cated that implementing use of bundles for insertion of 
central venous catheters decreases the incidence of 
CLABSI. Bundle elements include performing hand 
hygiene, using CHG for skin cleansing, and instituting 
full-barrier precautions before insertion of the cathe-
ter.43 Having registered nurses assist in insertion of cen-
tral venous catheters and monitor bundle compliance 
is an important step in preventing CLABSI. The Joint 
Commission44 recommends having nurses complete an 
insertion checklist that incorporates these bundle ele-
ments as a patient safety measure. 
Empowering nurses to stop the insertion if breaks 
in sterile technique occur is critical in minimizing the 
threat of bacterial migration into the bloodstream. The 
need for central venous catheters should be reassessed 
frequently, and any unnecessary devices should be removed 
to decrease the risk of CLABSI.11 Once the catheters are 
placed, nurses should actively survey the site for signs 
of infection, including erythema, warmth, and purulent 
drainage. If the site becomes infected, a physician or a 
midlevel provider should be notified promptly. In these 
instances, removal of the catheter is recommended by 
the Centers for Disease Control and Prevention.11
For patients with bacteremia or other severe infections 
caused by MRSA or other multidrug-resistant organisms, 
response to treatment must be assessed. Up to 1 week 
may be required after the start of treatment with appro-
priate antibiotics before blood cultures indicate eradica-
tion of MRSA. If a patient’s clinical status is worsening 
despite antibiotic therapy, the causative organism may 
be resistant to the current medication.6 The patient’s 
clinical status should be correlated to laboratory values, 
especially the white blood cell count. A decrease in the 
white blood cell count is not always an indication the 
antibiotic is effective. 
Drug-induced neutropenia is associated with some 
classes of medications, including anti-infectives. The 
neutropenia usually occurs within 2 to 60 days after 
administration of a drug.45 Drug-induced neutropenia 
increases the risk for sepsis and may predispose patients 
to hospital-acquired infections. Superinfections can also 
result from 
antibiotic 
use. Moni-
toring is 
required for 
the develop-
ment of oral thrush, vaginal yeast infections, and other 
superinfections, as well as Clostridium difficile–associated 
diarrhea.16 Vancomycin, linezolid, and ceftaroline may 
decrease bone marrow production. Monitoring the  
complete blood cell count can help detect neutropenia,  
anemia, and thrombocytopenia before these blood 
abnormalities become clinically relevant.
The bactericidal activity of vancomycin depends on 
the ratio of the area under the curve to the MIC of van-
comycin for the organism in question. Trough levels are 
used as a surrogate marker to ensure a target ratio greater 
than 400. Correct timing is essential in obtaining blood 
samples to determine trough levels. Measurements of 
vancomycin troughs are most accurate when the medi-
cation has reached its steady state. The blood samples 
should be obtained just before the fourth dose in patients 
Registered nurses can help prevent 
CLABSI by assisting in insertion of 
central venous catheters and monitoring 
bundle compliance.
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with normal renal function.13 If a blood sample is obtained 
too early, the level will be higher than it would be if the 
sample were obtained at the correct time. In a retrospective 
analysis of 2597 blood samples obtained during a 
13-month period, Morrison et al46 found that more than 
41.3% of the samples obtained to measure vancomycin 
troughs were obtained too early. The samples that were 
obtained early yielded higher trough levels than did sam-
ples obtained at the appropriate time. Measurements that 
inaccurately indicated elevated levels may prompt the 
provider or clinical pharmacist to inappropriately adjust 
subsequent vancomycin doses.47 Subtherapeutic levels 
can lead to vancomycin-resistant bacteria and potential 
treatment failures.13 
Patient Education
Because MRSA CLABSIs typically require a minimum 
of 14 days of antibiotic therapy after the first blood cul-
ture is negative for the microbe, some patients will be 
discharged before they complete their course of treat-
ment.6,11 At the time of discharge, general education for 
patients taking antibiotics to treat MRSA CLABSIs should 
focus on reminding the patients to take the drugs as 
instructed, not skip doses, and not stop the medication 
until the 
course of 
therapy is 
finished. 
Discharge 
education 
should 
include information on the potential adverse effects of 
the antibiotic, including superinfections and Clostridium 
difficile–associated diarrhea. Patients should be educated 
on the signs and symptoms to look for and when to 
notify the prescribing health care provider. 
Counseling patients on preventing the spread of MRSA 
to others is important. Hand hygiene keeps MRSA from 
spreading. Hand washing is preferable, but alcohol- 
based gel hand sanitizers are also effective, except for 
Clostridium difficile–associated diarrhea. Patients should 
cover all draining wounds to prevent transmission of the 
bacteria. Because patients usually have some type of 
long-term venous access, such as a peripherally inserted 
central catheter, they and their family members should 
be instructed on proper care of the catheter and use of 
aseptic technique before, during, and after each 
administration of antibiotic. Patients should be educated 
about the signs of infection at the catheter site and be 
instructed to notify their provider if infection occurs.48 
Patients and caregivers assisting with dressing changes 
must wear gloves during wound care and must wash 
their hands immediately after. Family members should 
be warned to avoid sharing personal or hygiene items 
with the patient. Nurses should encourage frequent 
cleaning of surfaces with which the patient infected with 
MRSA comes into contact with a product labeled as a dis-
infectant. The agent must stay in contact with the con-
taminated surface for 10 minutes. Clothing and linen 
should be laundered frequently. If wound drainage is 
present, these items should be washed daily.6 Additionally, 
patients with active MRSA infections should avoid par-
ticipating in contact sports and in exercising at public 
facilities such as gyms until the patients are cleared by 
their health care provider.
Conclusions
Vancomycin has remained the agent of choice for 
treating MRSA bacteremia for several decades.6,9 Recent 
research supports use of alternative agents for MRSA 
bacteremia, but the use of these agents is often reserved 
for patients who cannot tolerate vancomycin, have per-
sistent bacteremia during treatment with vancomycin, or 
have MRSA infections for which vancomycin MICs are 
elevated.6,9,22,23,25,26,38 Daptomycin has the most data to 
support its use as an alternative agent in MRSA bactere-
mia in both the IDSA 2009 CLABSI and 2011 MRSA 
guidelines. Linezolid should be reserved for salvage 
therapy.6,9 In addition, ceftaroline has increasing retro-
spective clinical data to support its use as an alternative 
agent in MRSA bacteremia, including CLABSIs, and in 
patients in whom standard therapy has been unsuc-
cessful.35-40 Recently, 3 new MRSA-active agents have 
been approved by the FDA: dalbavancin, oritavancin, 
and tedizolid. All 3 agents have activity against MRSA, 
but currently no data are available to support their use 
in MRSA bacteremia or CLABSIs.49-51 Unfortunately, 
resistance to available antibiotics is occurring quicker 
than new agents are being developed.52 Antimicrobial 
stewardship efforts to ensure the optimal prescribing of 
these available broad-spectrum anti-MRSA antibiotics 
are needed to help decrease the development of multi-
drug-resistant organisms.53 In addition to preventing the 
development of resistant organisms, evidence-based 
Accurate and reliable measurements of 
vancomycin troughs are achieved with 
correct timing of previous doses and 
when the medication has reached its 
steady state.
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practices such as isolation, proper cleaning of high-touch 
surfaces, and CHG bathing to decrease bacterial load are 
essential in preventing the spread of MRSA. 
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d tmore
To learn more about caring for patients with methicillin-resistant 
Staphylococcus aureus, read “Nasal Colonization and Lower Respira-
tory Tract Infections With Methicillin-Resistant Staphylococcus 
aureus” by Tilahun et al in the American Journal of Critical Care,  
January 2015; 24:8-12. Available at www.ajcconline.org.
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Treating Central Catheter–Associated 
Bacteremia Due to Methicillin-Resistant 
Staphylococcus aureus: Beyond Vancomycin
Holt S, Thompson-Brazill KA, Sparks ER, Lipetzky J. Treating Central Catheter–Associated Bacteremia Due to Methicillin-Resistant Staphylococcus aureus: 
Beyond Vancomycin. Critical Care Nurse. 2016;36(4):46-57.
According to the Centers for Disease Control and Pre-
vention, methicillin-resistant Staphylococcus aureus 
(MRSA) is a leading cause of heath care–associated infec-
tions. Colonization can lead to infection when a breach 
occurs in the skin or mucosal defense systems because of trauma 
or common procedures such as surgery or placement of a 
central catheter. 
MRSA is a common cause of bacteremia and is the caus-
ative organism reported in 7.4% of central catheter–associated 
bloodstream infections (CLABSIs) in critical care patients. 
Most patients with suspected CLABSI are given vancomycin 
because of the increased prevalence of MRSA in health care 
settings, and combination therapy with a drug effective against 
a broad spectrum of gram-negative organisms should be con-
sidered for patients who are critically ill or immunocompromised. 
Vancomycin
• Treatment of a CLABSI depends on the causative organ-
ism, removal of the infected catheter, patient-specific 
factors, and complications. Vancomycin is the first-line 
option for treatment of documented MRSA bacteremia. 
• Determining the best dosage of vancomycin is difficult, 
tissue penetration is highly variable, routine trough-level 
monitoring is required, and infusion-rel ated reactions 
and anaphylaxis can occur. 
• The Infectious Diseases Society of America vancomycin 
guidelines suggest that an alternative agent should be 
considered in MRSA infections for which the vancomycin 
minimum inhibitory concentration is 2 μg/mL or less, 
particularly if the patient is not responding to treatment. 
• Although vancomycin remains the drug of choice, alter-
native agents may be used to treat invasive MRSA infec-
tions, including daptomycin (Cubicin), linezolid 
(Zyvox), telavancin (Vibativ), tigecycline (Tygacil), and 
ceftaroline (Teflaro).
Nursing Care
• Instituting evidence-based infection control measures is 
required to prevent the spread of MRSA and other  
multidrug-resistant organisms. Studies have shown that 
decreasing the skin’s bacterial load with chlorhexidine 
gluconate baths decreases rates of infection.
• Implementing use of bundles for insertion of central 
venous catheters decreases the incidence of CLABSI. 
Bundle elements include performing hand hygiene, 
using chlorhexidine gluconate for skin cleansing, and 
instituting full-barrier precautions before insertion of 
the catheter. 
• Having registered nurses assist in insertion of central 
venous catheters and monitor bundle compliance is 
an important step in preventing CLABSI.
• Empowering nurses to stop the insertion if breaks in 
sterile technique occur is critical in minimizing the 
threat of bacterial migration into the bloodstream. 
• Superinfections can result from antibiotic use. Moni-
toring is required for the development of oral thrush, 
vaginal yeast infections, and other superinfections, as 
well as Clostridium difficile–associated diarrhea.
• Counseling patients on preventing the spread of MRSA 
to others is important. Hand hygiene keeps MRSA from 
spreading. Hand washing is preferable, but alcohol- 
based gel hand sanitizers are also effective, except for 
Clostridium difficile–associated diarrhea. 
• Patients should cover all draining wounds to prevent 
transmission of the bacteria. 
• Patients and their family members should be instructed 
on proper care of the catheter and use of aseptic tech-
nique before, during, and after each administration of 
antibiotic. Patients should be educated about the signs 
of infection at the catheter site and be instructed to 
notify their provider if infection occurs. 
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